Editas Medicine

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with additional facilities in Boulder, Colorado. Founded in 2013 by pioneers in genome editing, including Feng Zhang and Jennifer Doudna, the company specializes in developing genomic medicines using CRISPR gene editing technology. The company focuses on *in vivo* gene editing therapies to treat serious diseases by correcting genetic causes at the molecular level. Editas is advancing a pipeline of gene editing therapeutics, including its lead candidate, EDIT-101, which targets Leber congenital amaurosis type 10, a rare genetic eye disease. The company is also developing treatments for hematologic diseases like sickle cell disease and beta-thalassemia, as well as collaborating with Bristol Myers Squibb and Immatics N.V. to create innovative cancer therapies. Editas aims to provide durable, potentially curative treatments for patients with serious and rare genetic disorders, blood diseases, and various cancers.